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Abstract
Objective—Microalbuminuria is associated with increased risk of cardiovascular disease and
mortality. The objective of the study was to evaluate if HIV infection was an independent risk
factor for microalbuminuria.
Design—Cross sectional.
Methods—The relationship between HIV infection and microalbuminuria was assessed using
subjects enrolled in the study of Fat Redistribution and Metabolic Change in HIV Infection, which
consists of HIV-positive and control men and women. Participants with proteinuria (dipstick ≥1+)
were excluded.
Results—Microalbuminuria (urinary albumin/creatinine ratio, ACR>30 mg/g) was present in
11% of HIV infected, and 2% of control participants (P<0.001); a fivefold odds after multivariate
adjustment (odds ratio, 5.11; 95% confidence interval, 1.97–13.31; P=0.0008). Several
cardiovascular risk factors were associated with higher ACR in HIV participants: insulin
resistance (HOMA>4; 32%, P<0.0001), systolic blood pressure (21%, P=0.01 for 120–140 versus
<120 mmHg, and 43%, P <0.06 for >140 versus <120 mmHg), and family history of hypertension
(17%, P=0.03). Higher CD4 cell count was associated with lower albumin/creatinine ratio (−24%,
P=0.009 for 200–400 versus <200 cells/ml and −26%, P=0.005 for >400 versus <200 cells/ml).
Conclusion—HIV infection had a strong and independent association with microalbuminuria,
the severity of which was predicted by markers of insulin resistance, hypertension, and advanced
HIV infection. These associations warrant further investigation, as the increased prevalence of
microalbuminuria in HIV infection may be a harbinger of future risk of cardiovascular and kidney
diseases.
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Introduction
Renal disease manifesting as proteinuria or elevated creatinine has been described as a
common complication of HIV infection. Among a cohort of women with HIV infection,
39% of African–American and 25% of Caucasian women had clinically significant
proteinuria [1]. These levels of proteinuria have subsequently been demonstrated to be
associated with poorer outcomes including an increased risk of hospitalization and mortality
[2–4]. Risk factors for clinically significant proteinuria include African–American race,
higher HIV RNA level, and lower CD4 lymphocyte count [1].
Similar to the data on prevalence of proteinuria, a strikingly high prevalence of
microalbuminuria among HIV-infected patients of 19%, 30%, and 34% has been described
in three studies [5–7]. One of these reports suggested that patients with `clinical AIDS' or
`AIDS related complex' may be at greater risk compared with asymptomatic HIV-infected
individuals [7]. Since the publication of these studies (1992, 1993, and 1996), the treatment
of HIV infection has changed dramatically. With the introduction of protease inhibitors and
highly active antiretroviral therapy, survival of patients with HIV infection has improved
substantially [8,9]. However, concurrent with this improved survival, changes in fat
distribution, worsening lipid profiles, and insulin resistance have also been noted [10–12].
Recent data indicate that the rate of cardiovascular disease is increased in patients with HIV
infection on combination antiretroviral therapy, although the role of antiretroviral therapy
and abnormalities of body composition is debated [13,14].
Microalbuminuria is a marker of renal damage that is associated with increased risk of
cardiovascular disease and mortality in the general population [15–18]. Given these
associations, microalbuminuria may be an important early marker of cardiovascular disease
risk in persons with HIV infection [19,20]. We hypothesized that HIV infection would be
associated with greater prevalence of microalbuminuria compared with similarly aged
controls. Using the Study of Fat Redistribution and Metabolic Change in HIV Infection
(FRAM) cohort, comprised of both HIV-infected and control participants, this study was
undertaken to compare the prevalence of microalbuminuria in each group and explore
predictors of microalbuminuria among persons with HIV infection.
Methods
Subjects
Briefly, FRAM is a cross-sectional study with the overall objective to evaluate abnormalities
in fat distribution using measurement of regional subcutaneous adipose tissue (SAT) and
visceral adipose tissue (VAT) by magnetic resonance imaging in HIV-infected subjects and
control subjects, as well as physical examination and laboratory examination of metabolic
parameters. HIV-infected subjects were recruited from 16 HIV or infectious disease clinics
or cohorts during 1999. FRAM is representative of patients with HIV infection in the U.S.
[21]. Control subjects were recruited from two centers of the Coronary Artery Risk
Development in Young Adults (CARDIA) study [22]. CARDIA subjects were originally
recruited as a population-based sample of healthy 18–30-year-old white and African–
American men and women from four cities in 1985–1986 for a longitudinal study of
cardiovascular risk factors. Participants who agreed to the year 15 CARDIA examination
were approached to participate in FRAM. Eighty participants with significant proteinuria
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(≥1 by dipstick) and those identifying as non-White or non-Black were excluded from this
analysis. The protocol was approved by institutional review boards at all sites. The methods
have been described in detail previously [21,23].
Measurements
Albumin and creatinine concentrations were measured in spot urine specimens obtained in
67% (967/1451) of subjects. Urine albumin excretion was estimated using the albumin to
creatinine ratio (ACR) and calculated by dividing the spot urine albumin concentration by
the spot urine creatinine concentration [24–27]. Microalbuminuria was analyzed as both a
dichotomous variable defined as ACR>30mg/g and a continuous variable. Prior research
from the CARDIA cohort has found that the ability of ACR to approximate 24-h urine
albumin excretion differs somewhat by sex and race, due to differences in creatinine
production. Within HIV-infected subjects, we used ACR adjustment coefficients for women
and African–Americans that were derived by Jacobs and colleagues to reduce sex- and race-
related effects on ACR levels [28]. Serum creatinine was measured and creatinine clearance
was calculated using the Cockcroft–Gault formula [29]. The homeostatic method of
assessment (HOMA) was utilized to assess beta-cell function and insulin resistance using
basal (fasting) glucose and insulin concentrations [30]. Simply, HOMA provides a
framework to utilize these two parameters to estimate increasing insulin resistance (i.e., a
greater insulin level to achieve the same glucose level) and decreased beta-cell function (i.e.,
a greater glucose level given a degree of insulin sensitivity). Among HIV-infected subjects,
blood was drawn for determination of CD4 cell counts and HIV RNA by PCR and measured
in a single laboratory (Covance, Indianapolis, IN, USA).
Statistical analyses
Clinical and demographic variables were summarized for HIV-infected and control subjects
separately stratified on the presence or absence of microalbuminuria (ACR>30 mg/g).
Continuous and categorical variables were compared between groups based on the presence
or absence of microalbuminuria within cohort defined by HIV infection using Student's t-
test or Wilcoxon's rank-sum test and Pearson's chi-square or Fisher's exact test as
appropriate.
The first objective of our analysis was to evaluate whether HIV infection was independently
associated with a greater prevalence of microalbuminuria (ACR>30mg/g) compared with
the control population. Multivariable logistic regression was used with adjustment for other
predictors of microalbuminuria that were measured in both HIV-infected and controls.
These analyses were repeated using linear regression to evaluate the presence of HIV
infection as a predictor of ACR as a continuous variable; because of its skewed distribution,
ACR was log-transformed in all linear regression analyses. Variables tested to determine if
they confounded the association between ACR and HIV infection include demographics
(age, sex, race), medical history (presence of HIV infection, diabetes mellitus, or
hypertension; family history of kidney disease or hypertension), physical exam parameters
(systolic and diastolic blood pressure), laboratory parameters (the presence of urine glucose,
HOMA, social history (self-reported use of illicit drugs), medications (statins, ACE-I, anti-
hypertensives), and assessments of visceral and regional subcutaneous adipose tissue (VAT
and SAT) volume.
The second major objective of the analysis was to evaluate the determinants of ACR among
the HIV-infected participants. ACR was analyzed as a continuous variable based on its
previously described association with mortality [15]; we incorporated ACR adjustment
coefficients, derived by Jacobs and colleagues, to minimize sex and race effects on ACR
levels [28]. The first of these two models tested all of the variables listed above plus
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including HIV specific parameters [i.e., current HIV RNA level (log10), current CD4
lymphocyte count (log2), duration of HIV infection, and risk behavior for HIV acquisition].
The second of these two models included all variables listed above, HIV specific
parameters, and use or duration of individual antiretroviral medications (e.g., stavudine,
zidovudine, etc.) as well as classes of antiretroviral medications [nucleoside/nucleotide
reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors (NNRTI), or
protease inhibitors]. Duration or use of each antiretroviral agent, antiretroviral agent class,
and HAART as previously defined [22] were added to the model in a forward stepwise
manner. These models were fitted to logarithmic transformations of ACR to produce
estimated percentage differences in ACR levels. Multivariate regression models were built
using stepwise regression, with P=0.05 for entry and retention and with gender, age, and
ethnicity forced to be included in every model. Confidence intervals were determined using
the bias-corrected accelerated bootstrap method [31], with P values defined as the one minus
the highest confidence level that still excluded zero. This was necessary both because the
outcome appeared to be non-Gaussian, even after log transformation, and to control for
multiple important predictors. Model validity was also examined by testing for important
interactions, multicollinearity, outliers, etc. (Fig. 1)
Results
Microalbuminuria among HIV-infected and control participants
Characteristics of HIV infected participants and controls with and without microalbuminuria
are displayed in Table 1. In general, HIV-infected subjects with microalbuminuria (ACR >
30 mg/g) were more likely to be female (P = 0.02), African–American (P=0.0003), have an
elevated systolic or diastolic pressure or have hypertension (P=0.0003, 0.02, and 0.002,
respectively), and a lower nadir CD4 lymphocyte count (P=0.04) as compared with HIV-
infected subjects without microalbuminuria. Additionally HIV-infected subjects with
microalbuminuria had a trend toward more insulin resistance (greater mean HOMA) though
this was not statistically significant (P=0.08). Among control subjects, those subjects with
microalbuminuria had greater insulin levels, fasting glucose levels, measures of insulin
resistance, (i.e., HOMA) (P=0.04, 0.003, 0.01) and greater triglyceride levels (P=0.06).
There were no apparent associations with regional adipose tissue volumes (P values for
association with individual adipose tissue depot volumes were all > 0.49).
Association of microalbuminuria with HIV infection
Microalbuminuria (ACR > 30 mg/gm) was present in 83 (11%) of the HIV-infected subjects
and 5 (2%) of the controls (P < 0.001) (Fig. 1). In the univariate analysis, HIV-infected
subjects had a fivefold higher odds than controls of having microalbuminuria (OR=4.95, P =
0.0002; 95% CI, 1.98–12.38) (Table 2). After multivariable adjustment for other predictors
of micro-albuminuria, the presence of HIV infection remained the strongest predictor of
microalbuminuria (OR, 5.11; P = 0.0008; 95% CI, 1.97–13.31 for HIV infection) (Table 3).
Other predictors of microalbuminuria included African–American race, greater serum
triglyceride measurement, greater systolic blood pressure, and female gender. Similarly,
when ACR was analyzed as a continuous variable, in the multivariate model of subjects with
and without HIV infection, the presence of HIV infection was strongly associated with a
higher ACR level (58%; 95% CI, 39–82; P < 0.0001) compared to control participants.
Predictors of microalbuminuria among HIV-infected participants
Among participants with HIV infection, older age (P=0.02) and African–American race
(P=0.001) were associated with higher ACR. Interactions between ACR and both gender
and race were tested in separate models and were not significant (P>0.05). Several
traditional cardiovascular risk factors were strongly associated with higher ACR; these
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included insulin resistance (HOMA>4; P<0.0001), greater systolic blood pressure (P=0.01
for 120–140 mmHg versus < 120 mmHg, and P=0.06 for > 140 mmHg versus < 120
mmHg), family history of hypertension (P=0.03), and urine glucose (p=0.002). In contrast,
tobacco use (P=0.57) was not significantly associated with higher ACR.
HIV-specific risk factors associated with higher ACR were lower CD4 lymphocyte count
(P=0.009 for 200–400 versus <200 cells/ml, and P=0.005 for >400 versus <200 cells/ml),
current HIV RNA level (P=0.05), and current use of NNRTI (P=0.01). Current use of
NNRTI was the only ARV selected into the model (entrance criterion P<0.05) among
candidate predictors that included duration or use of each individual ARV, class of ARV,
and use of HAART regimens. Co-infection with hepatitis C virus (P=0.58) was not
significantly associated with higher ACR.
Discussion
This analysis demonstrated that HIV infection is a strong risk factor for the presence of
microalbuminuria, independent of other risk factors for the presence of renal disease.
Among HIV-infected individuals, risk factors for microalbuminuria included traditional HIV
specific markers such as CD4 lymphocyte count and HIV RNA level. The association of
HIV infection with albuminuria and proteinuria was reported in an earlier era of the HIV
epidemic in the USA with a prevalence of between 19 and 34% [5–7]. One of these prior
studies demonstrated associations between the presence of microalbuminuria and `stage' of
HIV-infection [7]. A more recent study also found that HIV RNA level, CD4 lymphocyte
count, and African–American race were important determinants of overt proteinuria [1]. In
the study described in this report, decreased CD4 cell count, increased viral load, and
African–American race were all associated with higher ACR.
However, higher albumin excretion rate in this study was also strongly associated with
several traditional renal and cardiovascular risk factors such as higher systolic blood
pressure, insulin resistance, and glycosuria [32,33]. The importance of these renal and
cardiovascular risk factors as determinants of albumin excretion rate in HIV-infected
individuals may mark a shift in the significance of microalbuminuria in the current era of
HIV in the USA. Rather than a marker of the severity of HIV infection and HIV-related
renal disease, the increased prevalence of microalbuminuria among HIV infected patients
may signal an increase in their cardiovascular risk.
Our findings indicate that within the HIV-infected population, non-HIV factors may be more
important predictors of microalbuminuria than HIV severity in the current era of HIV in the
USA. In particular, the cardiovascular risk factors of increased systolic blood pressure,
insulin resistance, and older age (risk factors previously noted in the general population)
were strongly associated with microalbuminuria in our HIV-infected cohort. These results
suggest that microalbuminuria may be a sign of current endothelial dysfunction and
microvascular disease rather than of advanced HIV infection in this cohort, and may thus
portend substantial risk of future cardiovascular disease events. Possible contributing factors
include early kidney disease such as HIV-associated nephropathy, a marker of end organ
damage related to comorbidities of diabetes mellitus or hypertension, or more diffuse
endothelial cells dysfunction. Nevertheless, after adjustment for non-HIV factors, HIV itself
is a major risk factor.
A relationship between microalbuminuria and current use of NNRTI was noted but was not
as strong as the association of microalbuminuria with other measures, such as HOMA and
CD4 lymphocyte count. While the potential for an indication bias related to the prescription
of a class of antiretroviral medications such as NNRTI is not intuitive, it does remain a
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possibility. However, clearly, the limited strength of the relationship in the setting of
multiple hypothesis-testing with dozens of individual and classes of medications should be
reflected in its interpretation. While certain antiretroviral medications have been associated
with acute renal failure and nephrolithiasis [34–37], glomerular damage has not previously
been reported with those medications and they were not apparently associated with
microalbuminuria in this study. Tenofovir use was very low at the time of study; indinavir
use was not associated with microalbuminuria.
Given the recent findings that even a very low ACR is a predictor of cardiovascular disease
and death [38], a similar correlation of these findings with outcomes in HIV-infected
persons as well as assessments of therapeutic interventions will be essential. Given the
analogous clinical scenario of a decrement in microalbuminuria with agents that disrupt the
renin–angiotensin axis among patients with diabetes mellitus [38], a similar therapeutic use
among HIV-infected persons with microalbuminuria is plausible.
While the strengths of this study include recruitment of subjects from 16 geographically
diverse centers, with subject demographics similar to those of HIV infected subjects in the
USA [21], this study does have important limitations. With respect to study design, it is
important to note that cross-sectional studies such as this may be affected by a survival bias.
Additionally, causation and whether treatment of predictors such as systolic blood pressure
and insulin resistance would decrease albuminuria in HIV cannot be determined from these
data.
In summary, the presence of HIV infection was independently associated with a fivefold risk
of micro-albuminuria as compared with an age-matched cohort without HIV infection.
Cardiovascular risk factors appeared to be stronger predictors of microalbuminuria than
markers of HIV severity. Persons with HIV infection and microalbuminuria therefore appear
to potentially bear the burden of two separate pathologic processes: microvascular end organ
damage related to known vascular risk factors, and HIV specific processes such as the direct
viral infection of kidney cells [39]. The high prevalence of microalbuminuria among the
HIV infected could be a harbinger of future increased risks of both kidney and
cardiovascular disease. Further study defining the prognostic significance of
microalbuminuria among HIV-infected persons will be essential.
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Distribution of ACR among HIV-infected and control participants.
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Table 2
Microalbuminuria among HIV-infected patients and control subjects [urinary albumin/creatinine ratio (ACR)
> 30 mg/gm].
HIV positive patients (n = 760) Control subjects (n = 207) P
Median ACRa 5 (IQR, 8.5) 4 (IQR, 2.0)
With microalbuminuria [n (%)] 83 (10.9) 5 (2.4)
Unadjusted OR 4.95 (95% CI, 1.98–12.38) < 0.0001b
Adjusted ORc 5.11 (95% CI, 1.97–13.31) 0.0008
a




Adjusted for race, serum triglyceride measurement, human insulin and systolic blood pressure, via logistic regression. IQR, Interquartile range;
OR, odds ratio; CI, confidence interval.
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Table 3
Results of multivariate model assessing association of HIV-related and non-HIV-related factors with urine
ACR in HIV-infected subjects.
Variable Effect [% (95% CI)] P
Age (per decade increase) 10.5 (1.7 to 20.4) 0.02
Sex
 Female versus male −14.8 (−28.0 to 3.3) 0.10
Race
 African-American versus Caucasian 33.0 (13.0 to 54.7) 0.001
HOMA > 4 32.4 (15.2 to 53.3) < 0.0001
Systolic blood pressure
 120–140 versus < 120 mmHg 20.6 (3.5 to 40.5) 0.010
 > 140 versus < 120 mmHg 43.2 (−0.9 to 108.4) 0.06
Family history of hypertension 16.6 (1.5 to 33.0) 0.03
Urine glucose (present versus absent) 113.2 (33.9 to 222.2) 0.002
Current CD4 lymphocyte count
 200–400 versus < 200 cells/ml −23.8 (−39.2 to −5.2) 0.009
 >400 versus < 200 cells/ml −25.7 (−40.3 to −8.3) 0.005
Current HIV RNA level (per 10-fold increase) 8.7 (0.1 to 19.0) 0.05
Current use of NNRTI 21.9 (4.5 to 41.6) 0.01
HOMA, homeostatic method of assessment; NNRTI, non-nucleoside reverse transcriptase inhibitor.
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